Paragon 28

Paragon 28, Inc. engages in operation of an orthopedic foot and ankle company. Its products include bone graft harvest system, bone marrow aspirate kits, and soft tissue fixation system. The company was founded by Albert DaCosta, Frank Bono, Jim Riegler and Lee Rosenthal in 2010 and is headquartered in Englewood, CO.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Paragon 28 reports strong revenue growth and strategic initiatives outlook

Paragon 28 delivered robust financial results in Q4 2022 and full-year 2022, driven by strong revenue growth in the U.S. and international markets.
While facing challenges in achieving profitability and commercializing new technologies, the company's focus on innovation and market expansion presents opportunities for future growth.
With a solid liquidity position and strategic initiatives in place, Paragon 28 is well-positioned to capitalize on market opportunities and drive continued performance.
Investors can look forward to the company's projected revenue growth in 2023 and advancements in technology adoption for improved patient outcomes.

Paragon 28 reports record Q1 revenue, eyes global growth opportunities

Paragon 28 delivered robust financial performance in Q1 2023, driven by strong revenue growth in the U.S. and internationally. While challenges in achieving profitability persist, the company's strategic focus on product development and global market expansion positions it for continued success. Opportunities for growth include optimizing sales force efficiency, launching new products, and capitalizing on international market strength.

Paragon 28 reports strong Q2 performance, eyes international expansion

Paragon 28's Q2 2023 earnings call reflects robust financial performance, driven by international growth and successful product launches.
While facing supply chain challenges and anticipating a growth slowdown, the company remains focused on expanding its market reach and product offerings.
Investments in key markets and a strategic focus on emerging growth drivers underscore Paragon 28's commitment to sustained revenue growth.
Prudence in guidance and operational planning amidst uncertainties highlights the company's proactive approach to managing challenges and seizing opportunities.

Paragon 28 reports steady Q3 growth amidst supply chain challenges

Paragon 28's Q3 2023 earnings call highlighted steady revenue growth, product innovation, and strategic investments driving performance.
While facing supply chain challenges and billing day impacts, the company's focus on market-specific strategies and surgeon training remains a strength.
Securing a new credit facility and reaffirming revenue guidance underscore Paragon 28's commitment to future growth and market leadership.

Paragon 28 reports robust Q4 performance, eyes growth in 2024

Paragon 28's strong performance in Q4 2023, coupled with expectations for growth in 2024, positions the company well for the future. Despite challenges like supply chain issues, the company's focus on innovation and market expansion presents significant opportunities. By maintaining accountability and leveraging market opportunities, Paragon 28 aims to drive continued success.

Paragon 28 reports record Q1 revenue, eyes growth opportunities

Paragon 28's Q1 2024 performance reflects strong revenue growth and strategic product launches.
While facing challenges like negative cash flow and increased SG&A expenses, the company remains optimistic.
Opportunities lie in upcoming product launches, market expansion, and engagement with investors.
Overall, Paragon 28's resilience and growth trajectory position it well for future success in the medical devices sector.

Paragon 28 reports record revenue and positive EBITDA in Q3

Paragon 28's Q3 2024 performance reflects strong revenue growth, product innovation, and a milestone in positive adjusted EBITDA post-IPO.
The company's emphasis on operational efficiency and cost optimization positions it well for sustained profitability and growth.
While facing challenges in cash flow and margin stabilization, Paragon 28 has opportunities to capitalize on its strengths and drive further expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will virtually present at the 24th Annual Needham Growth Conference on Monday, January 10th. The presentation will be webcast live on Monday, January 10, 2022, at 2:45pm ET / 12:45pm MT. The webcast, as well as the archived recording, will be availa

Paragon 28 to Present at 24th Annual Needham Growth Conference

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) announced today that it has received a supplemental approval order from the U.S. Food and Drug Administration ("FDA") for the Patient Specific Talus Spacer. The supplemental approval order allows the Patient Specific Talus Spacer to be additively manufactured in titanium alloy with a titanium nitride coating. The Patient Specific Talus Spacer was first approved on February 17, 2021, by the FDA under a Humanitarian Device Exemption

Paragon 28's Patient Specific Titanium Talus Spacer Has Been Approved by the U.S. Food and Drug Administration

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of B. Kristine Johnson and Kristina Wright to the Board of Directors, effective December 1, 2021. “I am very pleased to welcome Kris Johnson to our board of directors, as she brings a breadth of med-tech industry leadership and commercial strategy expertise. Kris' expertise in growing medical de

Paragon 28 Announces Addition of B. Kristine Johnson and Kristina Wright to its Board of Directors

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will virtually present at the Piper Sandler 33rd Annual Virtual Healthcare Conference. Management will also be hosting virtual investor meetings on November 30 and December 1. The pre-recorded fire-side chat will be available for on-demand viewing beg

Paragon 28 to Present at Piper Sandler 33rd Annual Healthcare Conference

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and nine months ended September 30, 2021. Financial Highlights Net revenue $35.9 million for the third quarter of 2021, representing 18% and 45% growth over the third quarters of 2020 and 2019, respectively, driven by sales channel expansion and new product revenue Net revenue $

Paragon 28 Reports Third Quarter 2021 Financial Results and Provides 2021 Fourth Quarter Net Revenue Guidance

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced today that the U.S. Food and Drug Administration (FDA) has given 501(k) marketing clearance to its Circular External Fixation System. The Circular External Fixation System, expected to commercially launch in early 2022, will complement Paragon 28's comprehensive internal fixation portfolio and further expands P

Paragon 28, Inc. Circular External Fixation System Cleared by FDA

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter of 2021 before market open on Monday, November 22, 2021. The company's management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (844-200-6205) for do

Paragon 28 To Report Third Quarter 2021 Financial Results on November 22, 2021

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a public offering price of $16.00 per share, for total gross proceeds of $125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares are being offered and sold by

Paragon 28, Inc. Announces Pricing of Initial Public Offering

News for Paragon 28 Stock (FNA)